Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 7, pp 1811–1818 | Cite as

Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis

  • Ondrej Fabian
  • Ondrej Hradsky
  • Tereza Drskova
  • Filip Mikus
  • Josef Zamecnik
  • Jiri Bronsky
Original Article

Abstract

Background

Diagnosis of pediatric inflammatory bowel diseases (IBD) remains challenging. We aimed at the value of immunohistochemical assessment of CD30+ lymphocytes in the intestinal mucosa in differential diagnosis between pediatric Crohn’s disease (CD) and ulcerative colitis (UC) and its utility as a predictor of future differentiation in patients with IBD unclassified (IBDU).

Methods

Seventy-four treatment naive pediatric patients with IBD (33 CD, 30 UC and 11 IBDU) were enrolled into the study. Biopsy samples from six different regions (terminal ileum, cecum, ascending colon, transverse colon, descending colon and rectum) were immunohistochemically stained with anti-CD30 antibody, and the number of positive cells per one high power field was quantified.

Results

Significant differences between CD and UC were found when compared total counts of CD30+ cells in median numbers, mean values and maximal numbers and also for separate counts in terminal ileum, transverse colon, descending colon and rectum. The most profound difference between CD and UC was shown for total median values of CD30+ cells and for the values in rectal localization. The difference was independent on the intensity of inflammation. A cutoff value of 2.5 CD30+ cells with sensitivity 83% and specificity 90% was found for the rectum. There was no difference between patients with CD and IBDU, but a marked difference between UC and IBDU patients was revealed.

Conclusion

Histopathological assessment of biopsy with rectal CD30+ count is reliable and simple method that could help in differential diagnosis among IBD subtypes in children with IBD.

Keywords

Inflammatory bowel disease Immunohistochemistry CD30 

Notes

Acknowledgments

We would like to thank Sara Wybitulova for reviewing the manuscript.

Funding

This work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00064203 (University Hospital Motol, Prague, Czech Republic) and the Grant Agency of Charles University in Prague, Project Nos. 136215, 364617 and 246216.

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

References

  1. 1.
    Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795–806.PubMedGoogle Scholar
  2. 2.
    Magro F, Gionchetto P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.CrossRefPubMedGoogle Scholar
  3. 3.
    Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.CrossRefPubMedGoogle Scholar
  4. 4.
    James SD, Wise PE, Zuluaga-Toro T. Identification of pathologic features associated with “ulcerative colitis-like” Crohn’s disease. World J Gastroenterol.. 2014;20:13139–13145.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Odze RD, Goldblum JR. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 3rd ed. New York: Elsevier; 2015:300.Google Scholar
  6. 6.
    Russo P, Ruchelli ED, Piccoli DA. Pathology of Pediatric Gastrointestinal and Liver Disease. 2nd ed. Springer; 2014:155–189, 233, 238.Google Scholar
  7. 7.
    Geboes K. What histologic features best differentiate Crohn’s disease from ulcerative colitis? Inflamm Bowel Dis. 2008;14:5168–5169.CrossRefGoogle Scholar
  8. 8.
    Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827–851.CrossRefPubMedGoogle Scholar
  9. 9.
    Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.CrossRefPubMedGoogle Scholar
  10. 10.
    Levine A, de Bie CL, Turner D, et al. Atypical disease phenotypes in paediatric ulcerative colitis: 5-year analyses of the EUROKIDS registry. Inflamm Bowel Dis. 2013;19:370–377.CrossRefPubMedGoogle Scholar
  11. 11.
    Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653–674.CrossRefPubMedGoogle Scholar
  12. 12.
    Turner D, Levine A, Escher JC, et al. Joint ECCO and ESPGHAN evidence-based consensus guidelines on the management of pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2012;55:340–361.CrossRefPubMedGoogle Scholar
  13. 13.
    Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification of inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.CrossRefPubMedGoogle Scholar
  14. 14.
    IBD Working Group of the European Society for. Paediatric Gastroenterology Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis—the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1–7.CrossRefGoogle Scholar
  15. 15.
    Cuffari C. Diagnostic considerations in pediatric inflammatory bowel disease management. Gastroenterol Hepatol. 2009;11:775–783.Google Scholar
  16. 16.
    Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207.CrossRefPubMedGoogle Scholar
  17. 17.
    Dave M, Papadakis KA, Faubion WA Jr. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin N Am. 2014;43:405–424.CrossRefGoogle Scholar
  18. 18.
    Flores C, Francesconi CF, Meurer L. Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease. J Crohns Colitis.. 2015;9:763–768.CrossRefPubMedGoogle Scholar
  19. 19.
    Bryant RV, Winer S, Travis SP, et al. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8:1582–1597.CrossRefPubMedGoogle Scholar
  20. 20.
    Fabian O, Hradsky O, Potuznikova K, et al. Low predictive value of histopathological scoring system for complications development in children with Crohn’s disease. Pathol Res Pract. 2017;213:353–358.CrossRefPubMedGoogle Scholar
  21. 21.
    Canavese G, Villanacci V, Antonelli E. Eosinophilia—associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. APMIS. 2017;125:179–183.CrossRefPubMedGoogle Scholar
  22. 22.
    Giuffrida P, Corazza GR, Di Sabatino A. Old and new lymphocyte players in inflammatory bowel disease. Dig Dis Sci. 2018;63:277–288.  https://doi.org/10.1007/s10620-017-4892-4.CrossRefPubMedGoogle Scholar
  23. 23.
    Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1–14.PubMedGoogle Scholar
  24. 24.
    Giacomelli R, Passacantando A, Parzanese I, et al. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn’s disease (CD). Clin Exp Immunol. 1998;111:532–535.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Sun X, Yamada H, Shibata K, et al. CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. J Immunol. 2010;185:7671–7680.CrossRefPubMedGoogle Scholar
  26. 26.
    Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet. 2016;387:156–167.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathology and Molecular Medicine, 2nd Faculty of MedicineCharles University and Motol University HospitalPrague 5Czech Republic
  2. 2.Department of Paediatrics, 2nd Faculty of MedicineCharles University and Motol University HospitalPrague 5Czech Republic

Personalised recommendations